Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
McKinsey
Mallinckrodt
AstraZeneca
Dow

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,377,453

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,377,453 protect, and when does it expire?

Patent 8,377,453 protects XARTEMIS XR and is included in one NDA.

This patent has nine patent family members in eight countries.

Summary for Patent: 8,377,453
Title:Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
Abstract: Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract ("GI") of a mammal for an extended period of time.
Inventor(s): Han; Chien-Hsuan (Sunnyvale, CA), Hou; Sui Yuen Eddie (Foster City, CA), Reid; Monica L. (San Mateo, CA)
Assignee: Depomed, Inc. (Newark, CA)
Application Number:12/402,477
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Device; Composition; Formulation; Process; Use;

Drugs Protected by US Patent 8,377,453

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mallinckrodt Inc XARTEMIS XR acetaminophen; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 204031-001 Mar 11, 2014 DISCN Yes No   Start Trial   Start Trial Y MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,377,453

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009223061   Start Trial
Canada 2720108   Start Trial
China 102105136   Start Trial
European Patent Office 2262484   Start Trial
Hong Kong 1152469   Start Trial
Japan 2011513499   Start Trial
Japan 5607550   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Boehringer Ingelheim
AstraZeneca
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.